Data / Drug companies / Sun Pharmaceutical Industries, Inc.
Sun Pharmaceutical Industries, Inc.: 269 products in the FDA NDC directory, labeler code 51672
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Sun Pharmaceutical Industries, Inc. (labeler code 51672) lists 269 products in the FDA National Drug Code Directory, covering 102 finished drugs by generic name. By type: 219 prescription drugs, 50 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 30, 2026.
The request: Watch Sun Pharmaceutical Industries, Inc. (FDA labeler code 51672): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 51672
- Products in commercial distribution
- 269
- Packages
- 612
- Finished drugs by generic name
- 102
- Prescription products
- 219
- Over the counter products
- 50
- Controlled substance products
- Schedule III 8, Schedule IV 12
- Flagged as original packager
- 240 of 240 products that carry the flag
- Started marketing in the last 12 months
- 15
- Earliest marketing start
- August 17, 1981
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 234 | 87% |
| Over the counter monograph drugs | 19 | 7.1% |
| Other unapproved drugs | 8 | 3% |
| New drug applications (NDA) | 7 | 2.6% |
| Authorized generics (NDA) | 1 | 0.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 219 | 81.4% |
| Over the counter drugs | 50 | 18.6% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Cream | 62 | 23% |
| Tablet | 52 | 19.3% |
| Solution | 26 | 9.7% |
| Ointment | 24 | 8.9% |
| Gel | 20 | 7.4% |
| Tablet, film coated | 13 | 4.8% |
| Suspension | 12 | 4.5% |
| Capsule | 10 | 3.7% |
| Lotion | 8 | 3% |
| Spray | 6 | 2.2% |
| Tablet, extended release | 6 | 2.2% |
| Aerosol, foam | 5 | 1.9% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Doxepin Hydrochloride | 51672-1404 | Cream | Generic drugs (ANDA) | September 30, 2026 |
| Hydrocortisone with Aloe | 51672-5335 | Cream | Over the counter monograph drugs | July 31, 2026 |
| Oxymetazoline Hydrochloride | 51672-1405 | Cream | Generic drugs (ANDA) | July 15, 2026 |
| Perampanel | 51672-4256 | Suspension | Generic drugs (ANDA) | June 16, 2026 |
| Acetaminophen 250 mg and Ibuprofen 125 mg | 51672-4258 | Tablet | Generic drugs (ANDA) | March 15, 2026 |
| Lamotrigine | 51672-4254 | Tablet | Generic drugs (ANDA) | March 1, 2026 |
| Lamotrigine | 51672-4255 | Tablet | Generic drugs (ANDA) | January 27, 2026 |
| Lamotrigine | 51672-4253 | Tablet | Generic drugs (ANDA) | January 27, 2026 |
| Lamotrigine | 51672-4252 | Tablet | Generic drugs (ANDA) | January 27, 2026 |
| Perampanel | 51672-4209 | Tablet, film coated | Generic drugs (ANDA) | November 25, 2025 |
| Perampanel | 51672-4208 | Tablet, film coated | Generic drugs (ANDA) | November 25, 2025 |
| Perampanel | 51672-4207 | Tablet, film coated | Generic drugs (ANDA) | November 25, 2025 |
| Perampanel | 51672-4206 | Tablet, film coated | Generic drugs (ANDA) | November 25, 2025 |
| Perampanel | 51672-4205 | Tablet, film coated | Generic drugs (ANDA) | November 25, 2025 |
| Perampanel | 51672-4204 | Tablet, film coated | Generic drugs (ANDA) | November 25, 2025 |
| Rivaroxaban | 51672-4228 | Tablet, coated | Generic drugs (ANDA) | October 15, 2025 |
| Polyethylene Glycol 3350 | 51672-2104 | Powder, for solution | Generic drugs (ANDA) | October 9, 2025 |
| Minoxidil Topical Solution 2% | 51672-2152 | Solution | Generic drugs (ANDA) | September 1, 2025 |
| Doxepin hydrochloride | 51672-4247 | Tablet | Generic drugs (ANDA) | August 7, 2025 |
| Doxepin hydrochloride | 51672-4246 | Tablet | Generic drugs (ANDA) | August 7, 2025 |
| Minoxidil Topical Solution, 5% | 51672-2151 | Solution | Generic drugs (ANDA) | August 1, 2025 |
| Lactulose | 51672-4243 | Solution | Generic drugs (ANDA) | June 2, 2025 |
| Hydrocortisone with Aloe | 51672-5330 | Cream | Over the counter monograph drugs | March 26, 2025 |
| Childrens Cetirizine Hydrochloride | 51672-2147 | Solution | Generic drugs (ANDA) | March 20, 2025 |
| Clotrimazole | 51672-2158 | Solution | Over the counter monograph drugs | September 23, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.